secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001125345-26-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports FY2025 net loss of $74.6M, cash $189.9M; pipeline data catalysts for 2026
--------------------------------------------------------------------------------

- Net loss $74.6M in 2025 vs $66.9M in 2024; revenue flat at $149.5M; cash $189.9M down from $201.7M.
- Phase 1 data for MGC026 (B7-H3 ADC) expected mid-2026; MGC028 (ADAM9 ADC) data in H2 2026.
- LINNET study of lorigerlimab under partial clinical hold; update expected mid-2026. IND for MGC030 on track for Q3 2026.
- Cash runway guidance extended into late 2027 based on current cash and partner payments.
- R&D expenses down 17% to $147.2M; SG&A down 45% to $39.2M due to cost reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/0001125345-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/mgnx-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001125345-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer